A-385358 Inhibitor

Solid. Powder

98.00%

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

639.83

DMSO: 125mg/mL (195.36mM) Need ultrasonic and warming
(<1mg/ml refers to the product slightly soluble or insoluble)

C32H41N5O5S2

O=C(NS(=O)(C1=CC=C(N[C@@H](CSC2=CC=CC=C2)CCN(C)C)C([N+]([O-])=O)=C1)=O)C3=CC=C(N4CCC(C)(C)CC4)C=C3

406228-55-5

Bcl-xL: ic50 0.8nM (ki)
Bcl-2: ic50 67nM (ki)

The combination of A-385358 given at 100mg/kg/d plus the lower dose of paclitaxel produces a significant reduction in tumor growth (%T/C) compare with paclitaxel monotherapy. This combination also yields a >100% increase in time for tumors to reach 900mM3 (%ILS) compare with vehicle control. Maximal efficacy is observed during the dosing period for A-385358, with slow but steady increase in the tumor growth after termination of treatment, The combination of A-385358 at 75mg/kg/d plus paclitaxel at 30mg/kg/d is also well tolerated and inhibits tumor growth rate by nearly 80%. Significant effects on tumor growth relative to paclitaxel monotherapy are observed with doses as low as 50mg/kg/d[1].

Apoptosis; BCL